BA
KERX

BlackRock Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

BlackRock Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$261K Sell
44,545
-1,108
-2% -$6.05K ﹤0.01% 2573
2016
Q3 		$242K Buy
45,653
+2,413
+6% +$13K ﹤0.01% 2584
2016
Q2 		$286K Sell
43,240
-4,602
-10% -$25.7K ﹤0.01% 2431
2016
Q1 		$223K Buy
47,842
+3,108
+7% +$12.4K ﹤0.01% 2499
2015
Q4 		$226K Sell
44,734
-21,002
-32% -$99.8K ﹤0.01% 2508
2015
Q3 		$231K Sell
65,736
-17,061
-21% -$114K ﹤0.01% 2637
2015
Q2 		$826K Buy
82,797
+19,920
+32% +$214K ﹤0.01% 1805
2015
Q1 		$800K Buy
62,877
+13,180
+27% +$169K ﹤0.01% 1707
2014
Q4 		$703K Sell
49,697
-2,374
-5% -$36.8K ﹤0.01% 1734
2014
Q3 		$716K Sell
52,071
-10,361
-17% -$159K ﹤0.01% 1683
2014
Q2 		$960K Sell
62,432
-48,297
-44% -$685K ﹤0.01% 1525
2014
Q1 		$1.89M Buy
110,729
+57,368
+108% +$866K ﹤0.01% 1201
2013
Q4 		$691K Buy
53,361
+3,284
+7% +$39.2K ﹤0.01% 1777
2013
Q3 		$505K Sell
50,077
-993,740
-95% -$8.84M ﹤0.01% 1901
2013
Q2 		$7.8M Buy
+1,043,817
New +$8.16M 0.01% 844

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Advisors's KERX Position: Q4 2016 in Review

BlackRock Advisors reduced its Keryx Biopharmaceuticals Inc (KERX) stake by 2.4% in Q4 2016, selling an estimated $6.05K and leaving 44,545 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #2573.

BlackRock Advisors first reported a position in KERX in Q2 2013 and has held it in 15 quarters since. The position peaked at $7.8M in Q2 2013. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

  • BlackRock Advisors held 44,545 shares of Keryx Biopharmaceuticals Inc worth $261K as of Q4 2016.
  • BlackRock Advisors sold 1,108 Keryx Biopharmaceuticals Inc shares in Q4 2016, an estimated $6.05K.
  • Keryx Biopharmaceuticals Inc made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2573 holding.
  • BlackRock Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Keryx Biopharmaceuticals Inc position peaked at $7.8M in Q2 2013.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.